Pediatric Infectious Diseases Department, Ali Asghar Children's Hospital, Iran University of Medical Sciences, Tehran, Iran.
J Infect Public Health. 2009;2(3):147-52. doi: 10.1016/j.jiph.2009.08.002. Epub 2009 Sep 23.
Prophylactic antibiotics are commonly used for prevention of urinary tract infections (UTIs) in children. It was postulated that the organisms and resistance patterns of breakthrough infections would differ with the choice of antimicrobial prophylaxis. This was a retrospective descriptive study of all breakthroughs UTI from 2000 to 2006 in children over 1 month of age discharged from a referral children's hospital in Tehran, Iran on continuous antibiotic prophylaxis for UTIs. Fifty-seven children discharged on prophylaxis had breakthrough UTIs of which 32 (56%) had a previously diagnosed urinary tract anomaly. Escherichia coli was responsible for the majority of infections irrespective of choice of prophylaxis. Thirty-three of 56 breakthrough UTIs (59%) were with organisms that were resistant to the prophylactic antibiotic. There was an increased incidence of resistance to prophylaxis in children on cefixime (16 of 22; 78%) when compared with children on cephalexin (7 of 19; 37%; p=0.02) and a trend toward increased resistance when compared with children on trimethoprim-sulfamethoxasole (3 of 8; 37%) (p=0.10). In conclusion, the resistance pattern of organisms causing breakthrough UTIs varies with the choice of prophylaxis which should be taken into consideration in chosing empiric therapy for such infections.
预防性抗生素常用于预防儿童尿路感染(UTI)。有人推测,突破感染的病原体和耐药模式会因抗菌预防药物的选择而有所不同。这是一项回顾性描述性研究,对 2000 年至 2006 年间,在伊朗德黑兰一家转诊儿童医院接受连续抗生素预防 UTI 治疗的 1 个月以上儿童中出现的所有突破 UTI 进行了研究。57 名接受预防治疗的儿童出现了 UTI 突破,其中 32 名(56%)有先前诊断的尿路异常。无论选择何种预防药物,大肠埃希菌都是引起感染的主要病原体。在 56 例 UTI 突破中,有 33 例(59%)病原体对预防用抗生素耐药。与头孢氨苄(7/19;37%)相比,头孢克肟组(16/22;78%)对预防用药的耐药率显著升高(p=0.02),与甲氧苄啶-磺胺甲噁唑组(3/8;37%)相比也有升高趋势(p=0.10)。总之,引起 UTI 突破的病原体的耐药模式随预防药物的选择而变化,在选择此类感染的经验性治疗时应考虑这一点。